Okay so essentially ATYR is a phase 3 drug company trading at 5.70 dollars (570m mcap) with a single drug focused on treating sarcoids with a novel idea of treatments. They have around 1.2 dollars per shares in cash with 1 year for runway. Long story short sarcoid has been a graveyard for drugs and ATYR MOA is hella questionable with q2 results being v questionable as well. If the trial succeeds it will go to 17ish and if it fails should be around 1.2 (cash) results are expected in the next two weeks but not guarenteed. So what's my position? I'm short vol with a small underlying short as well. My thesis is IV is way too high and theres a high chance of failure (>85%)
First with the vol side. I've sold 30% in 1 dollar october puts (20 cents a pop) Just using INMB, SAVA, CRDF as base cases where there was a fat fail and still traded above cash due to some post hoc subgroup
I've also sold a straddle on 5 dollars for 6.2 dollars total with 50% on october
lastly I took a short with 20% along with 12 dollar september calls (1 dollar) for coverage purposes.
So to go over my breakeven and percentage gains.
Max gain is at 1 by october 20th. Where I'll make 54% roughly
Loss break even is at .57 and 12 dollars ish, with 17 being a roughly 25% loss. Side note if you follow you almost have to use margin just because of the selling call/put cash requirements. LMK if u have any questions